2022
DOI: 10.21802/gmj.2022.2.6
|View full text |Cite
|
Sign up to set email alerts
|

The Mongoose Phenomenon: A New Logical Heuristic

Abstract: Often when discussing what is considered a rarer occurring event, individuals reference the Baader-Meinhof phenomenon as insurance against fallacious thinking. Also known as the frequency bias, this logical heuristic states that rare occurring events are rare and the knowledge of the existence of rare occurrences makes the interlocutor more likely to search out the event or see it occur more frequently. These false increases in observation frequency can logically be blamed, at least in part, on the interlocuto… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The patient presented a week later in a worse condition because he was not taking his antiplatelet therapy at home. It is well known that within 21 days after a stroking event, patients should be continuing 2 antiplatelet medications: clopidogrel/aspirin, ticagrelor/aspirin, ticagrelor/clopidogrel, as noted in the Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials [18].…”
Section: Discussionmentioning
confidence: 99%
“…The patient presented a week later in a worse condition because he was not taking his antiplatelet therapy at home. It is well known that within 21 days after a stroking event, patients should be continuing 2 antiplatelet medications: clopidogrel/aspirin, ticagrelor/aspirin, ticagrelor/clopidogrel, as noted in the Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials [18].…”
Section: Discussionmentioning
confidence: 99%